吡格列酮对2型糖尿病患者C反应蛋白及尿微量白蛋白作用探讨

Effect of Pioglitazone on CRP and MAU in Patients with Type 2 Diabetes Mellitus

目的:探讨吡格列酮(瑞彤)对2型糖尿病(DM)患者炎性标志物C-反应蛋白(CRP)及尿微量白蛋白(MAU)的作用。方法:测定90例血糖控制良好的2型DM患者,30例健康对照组血清CRP及MAU的量,然后对糖尿病组加用瑞彤15mg口服,每日一次,共24周。比较糖尿病组加用瑞彤前后血清CRP及MAU。结果:糖尿病组CRP高于健康对照组(P<0.01)。瑞彤治疗后糖尿病组CRP及MAU均较前明显下降(P<0.01)。结论:瑞彤能显著降低2型DM患者CRP水平及MAU,因此,瑞彤不仅能改善胰岛素抵抗作用,还能降低CRP水平及MAU,改善或减轻肾脏损害。

Objective：To investigate the effect of Pioglitazone on C-reactive protein（CRP） and micro- albumin urine（MAU） in patients with Diabetes Mellitus Methods： Ninety patients with type 2 Diabetes Mellitus who have satisfied blood glucose were recruited in the randomized - controlled study for 24 weeks. The blood levels of CRP and MAU were detected. Results： The levels of CRP in patients with Diabetes Mellitus were higher than that of healthy controllers（ P 〈 0.01 ）. After 24 weeks, the levels of CRP and MAU were significantly reduced by Pioglitazone in patients with Diabetes Mellitus（ P 〈 0.01 ）. Conclusion： In addition to improve insulin resistance, Pioglitazone may reduce levels of CRP and MAU, and ameliorate complication of kidney.